Euda Health Holdings Ltd. has announced a major expansion of its longevity and regenerative medicine strategy with the launch of a comprehensive stem cell therapy platform and the opening of its first longevity clinic in Shenzhen, China. The new clinic, established in partnership with KB International Ltd., will offer advanced stem cell and T-cell immunotherapies, personalized AI-guided life cycle management, and integrated Eastern, Western, and functional medicine services. Additionally, Euda is upgrading Shenzhen Inno's cGMP facility to enhance production capacity and innovation in stem cell treatments, leveraging proprietary iPSC technology and collaborations with leading Japanese partners. This expansion positions Euda at the forefront of the fast-growing longevity healthcare sector in Asia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9616469-en) on December 23, 2025, and is solely responsible for the information contained therein.